Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Literature DB >> 11181393

Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Abstract

The synergism of voriconazole (VRC) and terbinafine was studied by using 39 genotypically defined clinical Candida albicans isolates that were cross-resistant to fluconazole and VRC and serial isolates that gradually developed azole resistance. Synergy was noticed in 100% (eight of eight) of the strains that were resistant to VRC. Antagonism was not observed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2001 PMID： 11181393 PMCID： PMC90406 DOI： 10.1128/AAC.45.3.966-968.2001

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

9 in total

1. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.

Authors: F M Müller; M Weig; J Peter; T J Walsh
Journal: J Antimicrob Chemother Date: 2000-08 Impact factor: 5.790

2. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.

Authors: F Barchiesi; L Falconi Di Francesco; G Scalise
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

3. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.

Authors: M A Pfaller; S A Messer; S Coffmann
Journal: J Clin Microbiol Date: 1995-05 Impact factor: 5.948

4. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis.

Authors: R Nandwani; A Parnell; M Youle; C J Lacey; E G Evans; J Midgley; J Cartledge; D A Hawkins
Journal: Br J Dermatol Date: 1996-06 Impact factor: 9.302

5. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.

Authors: M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; A Monzón; J L Rodríguez-Tudela
Journal: Eur J Clin Microbiol Infect Dis Date: 1999-06 Impact factor: 3.267

6. Transmission of an azole-resistant isogenic strain of Candida albicans among human immunodeficiency virus-infected family members with oropharyngeal candidiasis.

Authors: F M Müller; M Kasai; A Francesconi; B Brillante; M Roden; J Peter; S J Chanock; T J Walsh
Journal: J Clin Microbiol Date: 1999-10 Impact factor: 5.948

7. Fluconazole-resistant Candida albicans after long-term suppressive therapy.

Authors: A Sanguineti; J K Carmichael; K Campbell
Journal: Arch Intern Med Date: 1993-05-10

8. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.

Authors: R Franz; S L Kelly; D C Lamb; D E Kelly; M Ruhnke; J Morschhäuser
Journal: Antimicrob Agents Chemother Date: 1998-12 Impact factor: 5.191

9. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

Authors: F Barchiesi; A L Colombo; D A McGough; M G Rinaldi
Journal: J Clin Microbiol Date: 1994-10 Impact factor: 5.948

9 in total

10 in total

1. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors: Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

2. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.

Authors: Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191

3. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.

Authors: Hua Quan; Ying-Ying Cao; Zheng Xu; Jing-Xia Zhao; Ping-Hui Gao; Xiao-Feng Qin; Yuan-Ying Jiang
Journal: Antimicrob Agents Chemother Date: 2006-03 Impact factor: 5.191

4. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.

Authors: Sofia Perea; Gloria Gonzalez; Annette W Fothergill; Deanna A Sutton; Michael G Rinaldi
Journal: J Clin Microbiol Date: 2002-05 Impact factor: 5.948

10. In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale.

Authors: Keita Sugiura; Akane Masumoto; Haruki Tachibana; Yoshiyuki Tatsumi
Journal: J Fungi (Basel) Date: 2021-03-12